Screener
Sionna Therapeutics SION Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Sionna Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: Sionna Therapeutics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 7:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033876
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Total current assets | 220,959 | 241,419 |
| Property and equipment, net | 2,071 | 2,225 |
| Marketable securities, noncurrent | 73,781 | 74,420 |
| Restricted cash | 963 | 963 |
| Operating lease right-of-use asset | 6,680 | 6,926 |
| Other assets | 585 | — |
| Total assets | $305,039 | $325,953 |
| Liabilities and stockholders’ equity |
Item 1. Financial Statements
FAQ
- What is Sionna Therapeutics's restricted cash?
- Sionna Therapeutics (SION) reported restricted cash of $963K in Q1 2026.
- How has Sionna Therapeutics's restricted cash changed year-over-year?
- Sionna Therapeutics's restricted cash increased by 0.1% year-over-year, from $962K to $963K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Sionna Therapeutics's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude